ALLIANCE for Clinical Trials in Oncology group in collaboration with the National Clinical Trials Network (NCTN)

375 mg/m2 on day 0 of cycle 1, then 500 mg/m2 on day 1 of cycles 2 to 6 (28 days each).

Patients on BR were able to cross over to IMBRUVICA® monotherapy within 1 year of investigator-assessed confirmed disease progression.

375 mg/m2 weekly for 4 weeks starting on day 1 of cycle 2, then on day 1 of cycles 3 to 6 (28 days each).

§PFS was assessed by investigators per iwCLL criteria.1